Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Interesting re Investigation

You'd have to assume that Reuters would only report the dividend story if there was a company source that they had received it from or at least confirmed it with. PTSC should be able to get that source name from Reuters, in an instance like this, I would assume.

If not, it would seem that either Reuters did not have the proper sources to print the story.

However, if they do have a "proper source", it would seem line they received info from someone in the company or someone claiming to be with the company. Either way, someone will be in some hot water here soon enough. I would expect that Reuters would be very cooperative in getting to the bottom of this.

Share
New Message
Please login to post a reply